Sulfonylureas as second-line therapy may cut diabetes costs

Data on type 2 diabetes patients showed those who used sulfonylurea drugs as a second-line agent attained improvements in glycemic control and quality-adjusted life years similar to other treatments. However, sulfonylureas yielded lower costs for patients compared with other regimens, researchers...

Share

This news summary appeared in DiabetesPro SmartBrief on 03/14/2014
Click here to view the full issue.


View the original article:
Healio (free registration)

Want to see more news summaries?
Sign up for DiabetesPro SmartBrief

DiabetesPro SmartBrief is a FREE, daily email newsletter that summarizes the day's top industry news from hundreds of sources. Each day, subscribers receive 8-10 headlines and news summaries like the one to the left
Sign up:
About SmartBrief
SmartBrief is the leading online publisher of targeted business news and information by industry. By combining technology and editorial expertise, SmartBrief filters thousands of sources daily to deliver the most relevant industry news in partnership with more than 180 trade associations, professional societies nonprofits and corporate entities